 |
|
|
|
 |
|
|
| Article 1 to 10 out of 14 concerning Abgenix, Inc.
|
-
Amgen Completes Acquisition of Abgenix
(04/05/2006)
Acquisition Provides Amgen with Full Ownership of Panitumumab and Eliminates a Denosumab Royalty
Amgen announced the completion of the acquisition of Abgenix, Inc., a company specializing in the discovery, development and manufacture of human therapeutic antibodies. Final regulatory approvals were received in January and Abgenix stockholders ...
-
Amgen to Acquire Abgenix
(12/19/2005)
Provides Amgen With Full Ownership of Panitumumab and Eliminates a Denosumab Royalty
Amgen and Abgenix, Inc. announced that they have signed a definitive merger agreement under which Amgen will acquire Abgenix for approximately $2.2 billion in cash plus the assumption of debt. Under the terms of the agreement, shareholders of ...
-
Panitumumab Significantly Improves Progression-Free Survival in Phase 3 Randomized Metastatic Colorectal Cancer Study
(11/07/2005)
First EGFr Inhibitor to Demonstrate Improvement in Progression-Free Survival as Monotherapy for Metastatic Colorectal Cancer
Amgen and Abgenix, Inc. announced that a pivotal Phase 3 study of panitumumab met the primary endpoint of improving progression-free survival in patients with metastatic colorectal cancer (mCRC) who had failed standard chemotherapy. In this ...
-
Abgenix and Amgen Announce FDA Grants Panitumumab Fast Track Designation for Metastatic Colorectal Cancer
(08/02/2005)
Amgen and Abgenix, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for panitumumab, an experimental fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFr), for ...
-
Abgenix to Consolidate Research Facilities in Preparation for Expanded Development and Commercial Operations
(06/30/2005)
Abgenix, Inc. announced that the company is consolidating its research and pre-clinical activities into the company's Canadian facility in Burnaby, British Columbia. With the consolidation, Abgenix maintains appropriate research capabilities and ...
-
Abgenix and Genentech Extend Antibody Technology Licensing Agreement
(03/16/2005)
Abgenix, Inc. announced that Genentech, Inc. has exercised its option to extend its technology licensing agreement with Abgenix for an additional three years. Under the extended agreement, Genentech will have access to Abgenix's proprietary antibody ...
-
Abgenix Appoints Donald R. Joseph as Senior Vice President, General Counsel and Secretary
(03/08/2005)
Abgenix, Inc. announced the appointment of Donald R. Joseph as Senior Vice President, General Counsel and Secretary. Mr. Joseph's appointment follows the departure of Susan L. Thorner, who resigned earlier this year to pursue other opportunities.Befo...
-
Cell Genesys Reports Fourth Quarter and Full Year 2004 Results
(01/27/2005)
Cell Genesys, Inc. reported a net loss for the quarter ended December 31, 2004 of $26.5 million, or $0.59 per share, and a net loss for the year then ended of $97.5 million, or $2.23 per share. This compares with a net loss of $17.3 million and a ...
-
Abgenix Appoints H. Ward Wolff as Chief Financial Officer
(09/09/2004)
Abgenix, Inc. (Nasdaq:ABGX) today announced the appointment of H. Ward Wolff as Chief Financial Officer and Senior Vice President, Finance, effective September 13."Ward brings over 25 years of finance, operating and management experience to Abgenix ...
-
Abgenix to Receive Milestone Payment from Amgen for Advancement of Antibody Candidate from Technology Licensing Agreement
(08/16/2004)
Abgenix, Inc. announced that it will receive a milestone payment from Amgen triggered by the advancement of AMG 162, a fully human antibody created using Abgenix's proprietary XenoMouse(R) technology, into a pivotal clinical trial. This is one of ...
|
|
|
|
|
Top
